|
Drug toxicity
|
0.300 |
Biomarker
|
group |
CTD_human |
Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.
|
19931604 |
2010 |
|
Adverse reaction to drug
|
0.300 |
Biomarker
|
group |
CTD_human |
Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.
|
19931604 |
2010 |
|
Cocaine Abuse
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Furthermore, these studies provide strong evidence for the potential usefulness of a suitable, stable, and long-acting form of CocE as a pharmacotherapy for cocaine abuse in humans.
|
19710369 |
2009 |
|
Cocaine-Related Disorders
|
0.300 |
Therapeutic
|
group |
CTD_human |
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats.
|
19710369 |
2009 |
|
Cocaine Dependence
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats.
|
19710369 |
2009 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.
|
17072980 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neither TOPO-1 nor CES-2 had significant correlation with age, gender, tumor site, tumor grade and metastatic sites in mCRC patients.
|
29261002 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, tissue adjacent to the tumor was a substantial source of CES-2 with high expression in plasma cells.
|
27149931 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High CES2 expression in tumor tissue was associated with longer overall survival in resectable and borderline resectable patients who underwent neoadjuvant FOLFIRINOX treatment (hazard ratio = 0.14, 95% confidence interval = 0.04 to 0.51, P = .02).
|
26025324 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A number of the predicted therapies were found to be active against the tumors in particular BGJ398 (FGFR2) and ICE-T. Re-transplanted ICE-T treated tumorgrafts demonstrated a decreased response to ICE-T recapitulating the patient's refractory disease.
|
24687871 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that the expression of CES2, UGTA1A1, and GUSB varies in colorectal pathology tissues and that the expression of CES2 is somewhat related to tumor staging.
|
24195516 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001).
|
23325581 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hepatic CES-2 mediated activation of irinotecan clearly correlated with tumour replacement by fibrosis (r (2) = 0.54, p = 0.01).
|
23756919 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No significant relationship was found between CES2 830C>G genotype and the toxicity and therapeutic efficacy (tumour response, event-free survival) of irinotecan in colorectal cancer patients.
|
17483951 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that the CES2Delta(458-473) transcript accounts for an average of 6% of total CES2 transcripts in colon tissue, and there is large interindividual variation in CES2 expression in both tumor and normal colon samples.
|
17636009 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When mice bearing s.c. MG-63 OS xenografts were intratumorally injected with Ad-sCE2 and CPT-11, this resulted in a significant difference in time to reach 2000 mm(3) in tumor volume as compared with animals receiving Ad-sCE2 or CPT-11 treatment (P < 0.05).
|
12939466 |
2003 |
|
Diarrhea
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In summary, glabridin was a potent and specific inhibitor targeting intracellular CES2A, which could be used as an ideal lead compound to develop more efficacious CES2A inhibitors for modulating the pharmacokinetic behaviors of CES2A-substrate drugs and alleviating irinotecan-induced diarrhea.
|
31260759 |
2019 |
|
Pancreatic carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor.
|
31803422 |
2019 |
|
Malignant neoplasm of pancreas
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor.
|
31803422 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In this study, we examined the relationship between <i>TP53</i> gene status and CES2 expression in human colorectal cancer.
|
29651325 |
2018 |
|
Diarrhea
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Co-administration with CES2 inhibitors may ameliorate CPT-11 associated lifethreatening diarrhea or improve the half-lives of CES2-substrate drugs.
|
29210644 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib in combination with R-ICE demonstrates tolerability and efficacy in rel/ref DLBCL, particularly of non-GC phenotype.
|
29386196 |
2018 |
|
Secondary malignant neoplasm of colon and/or rectum
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The correlation between TOPO-1 or CES-2 expression and clinicopathological characteristics of mCRC patients was analyzed.
|
29261002 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
|
28143954 |
2017 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CES-2 expression was analyzed by immunohistochemistry in colorectal cancer (CRC) compared to colonic inflammation as well as in liver and peripheral blood.
|
27149931 |
2016 |